market-trends is the sole category represented across all 1 tracked stories. Collegium Pharmaceutical, Inc. is most often covered alongside Belbuca, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Collegium Pharmaceutical, Inc. appears in 1 tracked Healthcare story from March 15, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Collegium Pharmaceutical, Inc.
market-trends is the sole category represented across all 1 tracked stories. Collegium Pharmaceutical, Inc. is most often covered alongside Belbuca, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Collegium Pharmaceutical, Inc. appears in 1 tracked Healthcare story from March 15, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 14 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Collegium Pharmaceutical, Inc.. Shared-story counts are live from our verified record — not editorial picks.
Eventide Asset Management LLC has reduced its position in Collegium Pharmaceutical, Inc. (COLL), though it maintains a significant $83.65 million stake. This institutional rebalancing occurs as the specialty pharmaceutical sector faces evolving regulatory scrutiny and a transition toward non-opioid pain management solutions.
Collegium Pharmaceutical, Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.